# Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination with Paclitaxel Chemotherapy

> **NCT05747794** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Immutep S.A.S.** · enrollment: 849 (estimated)

## Conditions studied

- Breast Carcinoma

## Interventions

- **BIOLOGICAL:** eftilagimod alpha
- **DRUG:** Paclitaxel
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT05747794
- **Lead sponsor:** Immutep S.A.S.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-22
- **Primary completion:** 2026-10-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 849 (ESTIMATED)
- **Last updated:** 2024-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05747794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05747794, "Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination with Paclitaxel Chemotherapy". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05747794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*